Commercialization
Why keep a drug after resistance emerges?
SAFFRON tested a regimen that retains EGFR inhibition against chemotherapy in lung cancer with high MET expression or amplification.
WEEKLY 009 · EDITION RECORD
Detecting Change and Following What Comes Next
A lung cancer combination after resistance, DNA barcodes that record infection, and dendrites that may protect old memories. This issue’s insight asks how using a drug earlier changes the time patients have and how they spend it.
Contents
3 readingsR&D Allocation
Using Detectron to read which phage was active in which bacterial strain
DNA barcodes distinguish phage and bacterial strain combinations. We examine the demonstrated performance and a possible use in tracking human airway recovery.
Frontier Science
Where are old memories protected when we learn something new?
A computational model asks how neurons can share memories while keeping learning-related changes on separate dendritic branches.
This issue’s insight: Does using a drug sooner buy time over the course of treatment? →
Topic states at issuance
Memory resilience
Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory.
- Next evidence
- Matched perturbations with different targets, fixed versus adaptive readout, and retention with or without relearning.
Shield: screening adoption
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
- Next evidence
- Track implementation, tests and payments, participation by previously unscreened people, and completed follow-up colonoscopies separately.
Therapy & companion diagnostics
Linked approval; uptake and payment open
- Next evidence
- Confirmatory evidence, payer policies covering the new use, and clinical adoption.
Compute for science
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
- Next evidence
- Check eligibility, collaborators, compute allocations, publication and IP terms. Deadline: December 1 at noon ET; decisions scheduled for March 1, 2027.
AI–scientist collaboration
Institutional report; independent verification open
- Next evidence
- Independent replication, public evaluation methods, and records of successes and failures from hypothesis to experiment.
After AI Finds a Candidate, What Gets Paid For?
The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs.
- Next evidence
- Use of contributed capacity, experimental outcomes, access and data-reuse terms, and demand after the support ends.
Who Will Build the Systems to Oversee Clinical AI?
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
- Next evidence
- Missed errors, false alarms, appropriate clinical handoffs and evaluation in routine care.
How Far Can Human Neural Tissue Compensate for Lost Function?
A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons.
- Next evidence
- Manipulate graft activity during specific tasks to distinguish modulation of host circuits from information processing.
Can measuring brain function help us choose an antidepressant?
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
- Next evidence
- Drug comparisons at the same treatment stage, and separate validation of early changes to inform subsequent decisions.
What Do New Cells Contribute to a Brain That Preserves Memories?
A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts.
- Next evidence
- Relate cell stage and circuit integration to memory retention, context discrimination and relearning.
Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
- Next evidence
- Track the authorized population and treatment conditions.
Transporting Cell Therapies Without Refrigeration
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
- Next evidence
- Storage duration by cell type, recovered function and independent ATCC testing.
Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
- Next evidence
- Patient selection, CSF-inclusive assessment, and ART5803 safety and clinical outcomes.
What Does Chugai Still See in a Drug Roche Is Walking Away From?
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
- Next evidence
- Patient selection, functional endpoints, long-term evidence and licensing terms.
Investing in another company's drug to advance your own
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
- Next evidence
- The planned OS analysis, detailed PFS results, and explanations of the population and safety findings.
What does an AI business sell when it helps run a clinical trial?
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
- Next evidence
- Selected teams, trial execution, payment by later sponsors and terms for model and patient-data use.
Using the same lesson across different actions, without confusing them
Mouse tasks with different actions and a shared reward delay showed shared cortical activity and task-dependent cerebellar separation that preserved temporal structure. A computational model combined faster learning with reduced interference.
- Next evidence
- Interference when representational separation is manipulated, transfer to novel tasks and which temporal relationships remain stable.
Changing treatment before scans show progression: a new relationship between breast cancer drugs and blood tests
European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression.
- Next evidence
- Comparison of early and post-progression use of the same drug, longer-term survival and uptake in the indicated population.
Does an antibody that binds well make a good development candidate?
A common-condition study of 511 sequences from 29 organizations found different performance in improvement and ranking tasks. Cradle’s high-affinity candidate passed the aggregate threshold but retained concerns in individual developability assays.
- Next evidence
- Reproducibility across targets, yield of candidates meeting required conditions, synthesis and assay counts, and cost and time to a development decision.
Can the same information remain readable as neural activity changes?
Flexible electrodes tracked the same mouse neurons over months. Aligning activity across recording days improved decoding of temporal information in a repeated movie. The analysis also used responses from the new day.
- Next evidence
- Distinguish reader adaptation from stable information components, and examine the learning that maintains their correspondence or its breakdown.
Enspryng expands into thyroid eye disease: a different target and a different way to treat
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
- Next evidence
- Follow disclosed new treatment starts, switches from other therapies and indication-specific sales in thyroid eye disease, separately from total Enspryng revenue.
Looking across diseases for drugs that treat fibrosis
3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
- Next evidence
- Candidates with shared responses across skin and lung models, conditions that separate responses, reproducibility across donor samples and subsequent development decisions.
Why does the same inflammation affect some fetuses but not others?
Within 24 hours of immune stimulation in mice, developmental abnormalities were reported in roughly 30% of fetuses, limited to a subset of males. Affected fetuses also showed placental inflammatory changes, structural disruption and immune-cell and cytokine accumulation in amniotic fluid.
- Next evidence
- Research separating placental inflammatory regulation, structural maintenance and developmental timing, and testing whether changing local conditions alters fetal outcomes.
From testing a patient's cancer to making their treatment
The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
- Next evidence
- Regulatory decisions, specimen-to-delivery time, manufacturing success, per-patient costs and indication-specific outcomes.
Building experimental data together for cell AI
The Virtual Biology Initiative expands joint experimental-data infrastructure. Separately, Arc’s 2026 challenge tests response prediction without providing perturbation outcomes in the target cells.
- Next evidence
- Added cells and interventions, independently evaluated predictive performance, and data-release and reuse conditions.
ACE levels are lower. Which functions have changed?
The study reports lower ACE protein abundance associated with early-stage psychosis and treatment resistance, but no significant group difference in enzyme activity per unit serum volume.
- Next evidence
- Separate abundance, activity and localization in patient-derived cells and mice; distinguish circuit and behavioral measures from blood-pressure and locomotor effects.
Why keep a drug after resistance emerges?
In phase 3 SAFFRON, 338 selected patients had median progression-free survival of 7.6 months with the combination and 5.4 months with chemotherapy.
- Next evidence
- Track the authorized population, testing criteria and the regimen’s place among later-line options.
Using Detectron to read which phage was active in which bacterial strain
The study distinguished three phages in E. coli and separately compared the response of six host strains to T7.
- Next evidence
- Test rare infections, cross-reactivity with related sequences and single-cell tag recovery and retention.
Where are old memories protected when we learn something new?
In a computational model, changing which dendritic compartments could undergo plasticity reduced interference between overlapping experiences.
- Next evidence
- Manipulate branch selection during new learning and distinguish effects on storage from effects on recall.
Record format & provenance
The archive stores complete article text, public evidence references, event dates, scheduled/observed distinctions, topic states and disclosed series. It contains no mailbox identifiers or private email bodies.
Editorial record window: 2026-11-05 — 2026-11-05 / Method: editorial-events-v1